Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first ever Phase IIIb imaging study primarily looking at the time course of r…
The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpointsAimovig showed superior tolerability an…
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a significant reduction in the rate of VOCs and to fewer days …
Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia Novartis global CAR-T manufacturing footprint now spans four continents, bringing Kymriah closer to patients …
Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2 Moderate-to-severe psoriasis affects more than 350,000 children worldwide3, with the physical and psycholog…
Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inh…
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19MP0420 and MP0423 are potential medicines with a uniqu…
Media ReleaseEnglish (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.3 MB) …
Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD): Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% …
C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the complement system’s al…